Device Transactions Device financing during 2015's third quarter reached $1.4 billion, a 22% dip from Q2's $1.8 billion total. ( See Exhibit 1. ) Late-stage venture capital rounds represented most of
Exact Sciences’ colorectal cancer test meets targets Preliminary results from the DeeP-C trial of Exact Sciences Corp. ’s Cologuard colorectal cancer screening test show the test has a specif